Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNG260 and Pembrolizumab in STK11 Mutated Advanced Solid Tumors
NCT05887492Phase 2Active, not recruiting
- Sponsor
- Tango Therapeutics
- Start
- Jun 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tng260 in solid tumor and non-small cell lung cancer (NSCLC) (4 arms), sponsored by Tango Therapeutics. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose at 42 days and Antitumor Activity by RECIST 1.1 at 12 weeks. Started Jun 2023; status: active, not recruiting.
02
Drugs
tng260
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05887492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05887492.